New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 19, 2012
08:15 EDTCGENCompugen announces $15M funding agreement for Korean subsidiary
Compugen announced the signing of an agreement with a private U.S.-based investment company pursuant to which up to $15M in milestone related equity financing will be made available to Keddem Bioscience Ltd., currently a wholly owned subsidiary of Compugen. This financing will be used to further develop and commercialize a unique technology platform that has been designed to consistently enable the discovery of small molecule modulators for potentially any given protein target. Under the agreement, the new investor will obtain a majority equity interest in Keddem, with Compugen maintaining a minority interest and certain future preferential access rights to utilize the Keddem technology with Compugen discovered drug targets.
News For CGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
07:12 EDTCGENCompugen to focus on ongoing programs during 2016
Company said, "This past year was a year of significant accomplishment for our company with respect to our unique discovery infrastructure and our target pipeline program. Another key achievement was the aggressive advancement of a second immune checkpoint program, CGEN-15029, which is our leading internal immuno-oncology program. Looking ahead, with substantially expanded capabilities and capacity, during 2016 our R&D focus will be on the advancement of these programs, the addition of immuno-oncology programs based on targets now undergoing validation, and further target discovery efforts."
07:10 EDTCGENCompugen reports Q4 EPS (1c), consensus (11c)
Subscribe for More Information
February 1, 2016
07:28 EDTCGENCompugen coverage assumed with an Outperform at Oppenheimer

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use